Index to Volume 43

The Index to Volume 43 is composed of three parts; an Author Index, a Subject Index and an Advertisers' Index.

Author Index

All contributing authors are listed alphabetically with the surname first and initials following. If there is more than one author, the submission title is documented under the author name which appeared first when published in the *Journal*. All other authors are listed referring to that name.

Subject Index

The Subject Index is comprised mainly of terms found in the "Key Words" section of abstracts, and also from principal words selected from titles listed in the Table of Contents of each issue. Separate sections in the Subject Index identify titles not found in the Table of Contents under the headings of "Book Reviews" and "Letters to the Editor". Also itemized separately are "Editorials" and the "President's Report". *Journal* and Society business can be found under *"Canadian Journal of Hospital Pharmacy"* and "Canadian Society of Hospital Pharmacists".

Advertisers' Index

The Advertisers' Index lists the company name followed by sub-headings of the products advertised. The issue number (as identified below) precedes the page number where the advertisement appears.

		Pages	
Number	Issue	Numerical	Arabic
1	February	1– 44	i–xx
2	April	45– 94	i–xxvi
3	June	95–154	i–xxvi
4	August	155–196	i–xxii
5	October	197–258	i–xxxii
6	December	259–310	i–xviii

Author Index

Andrews JD.
Pharmacy misses out on recognition (Letter) 5
see Jung B. 116
Misleading summary of cefoxitin (Letter) 158
see Trottier L. 249
Baetz, BW.
Parenteral packaging waste reduction 179
Bayliff CD
Free trip (Letter) 48
see Devlin JW. 134
Bayliff CD, Einarson TR.
Physician assessment of pharmacists' interventions — a method of estimating cost avoidance and determining quality assurance 167
Bennett J, Thompson DF.
Desensitization of ASA-intolerant patients 191
Bentur Y.
see Koren G. 57
Brown G.
see Hamilton D. 203
Brown G, Miyata M.
Improving pharmacy input in patient care through reorganization of clinical functions 131
Bryson SM.
see Dupuis LL. 101
see Leson CL. 82
see Ho K. 289
Birmingham CL.
see Kim-Sing A. 161
Burnham KE.
see Fisher CL. 75
Cameron A, Nessim D, Rovers J, Lavack L.
The use of a mini-accreditation program to prepare for a CCHFA accreditation survey 183
Caravaggio C.
Handbook of applied therapeutics — first edition (Book Review) 295
Chan J.
Adverse reactions associated with the misuse of TAC solution 190
Charbonneau F.
1990 professional practice conference 145
The 43rd annual general meeting 299
Collens SR.
see Nemethy EM. 61
Collins D.
see Reilly K. 27
Constable K.
Racepinephrine administration to children 34
Coons C.
see Walker S. 265
Crone K.
see Payne L. 247

Index to Volume 43

The Index to Volume 43 is composed of three parts; an Author Index, a Subject Index and an Advertisers' Index.

Author Index

All contributing authors are listed alphabetically with the surname first and initials following. If there is more than one author, the submission title is documented under the author name which appeared first when published in the *Journal*. All other authors are listed referring to that name.

Subject Index

The Subject Index is comprised mainly of terms found in the "Key Words" section of abstracts, and also from principal words selected from titles listed in the Table of Contents of each issue. Separate sections in the Subject Index identify titles not found in the Table of Contents under the headings of "Book Reviews" and "Letters to the Editor". Also itemized separately are "Editorials" and the "President's Report". *Journal* and Society business can be found under *"Canadian Journal of Hospital Pharmacy"* and "Canadian Society of Hospital Pharmacists".

Advertisers' Index

The Advertisers' Index lists the company name followed by sub-headings of the products advertised. The issue number (as identified below) precedes the page number where the advertisement appears.

		Pages	
Number	Issue	Numerical	Arabic
1	February	1– 44	i–xx
2	April	45– 94	i–xxvi
3	June	95–154	i–xxvi
4	August	155–196	i–xxii
5	October	197–258	i–xxxii
6	December	259–310	i–xviii

Author Index

Andrews JD.
Pharmacy misses out on recognition (Letter) 5
see Jung B. 116
Misleading summary of cefoxitin (Letter) 158
see Trottier L. 249
Baetz, BW.
Parenteral packaging waste reduction 179
Bayliff CD
Free trip (Letter) 48
see Devlin JW. 134
Bayliff CD, Einarson TR.
Physician assessment of pharmacists' interventions — a method of estimating cost avoidance and determining quality assurance 167
Bennett J, Thompson DF.
Desensitization of ASA-intolerant patients 191
Bentur Y.
see Koren G. 57
Brown G.
see Hamilton D. 203
Brown G, Miyata M.
Improving pharmacy input in patient care through reorganization of clinical functions 131
Bryson SM.
see Dupuis LL. 101
see Leson CL. 82
see Ho K. 289
Birmingham CL.
see Kim-Sing A. 161
Burnham KE.
see Fisher CL. 75
Cameron A, Nessim D, Rovers J, Lavack L.
The use of a mini-accreditation program to prepare for a CCHFA accreditation survey 183
Caravaggio C.
Handbook of applied therapeutics — first edition (Book Review) 295
Chan J.
Adverse reactions associated with the misuse of TAC solution 190
Charbonneau F.
1990 professional practice conference 145
The 43rd annual general meeting 299
Collens SR.
see Nemethy EM. 61
Collins D.
see Reilly K. 27
Constable K.
Racepinephrine administration to children 34
Coons C.
see Walker S. 265
Crone K.
see Payne L. 247

da Silva J.
see Hamilton D. 203
Davis SK.
see Landsberg KF. 139
DeAngelis C.
see Walker S. 265
Devlin JW, Bayliff CD, Paterson NAM.
Benzodiazepine withdrawal masquerading as steroid psychosis 134
Dupuis C.
Pre-eclampsia in twin pregnancy 186
Dupuis LL, Zahn D, Silverman ED, Bryson SM.
Palatability and relative bioavailability of an extemporaneous prednisone suspension 101

Eagleson D.
see Ruth S. 109
Einarson TR.
see Treleaven S. 17
see Bayliff CD. 167
see Jackevicius C. 273

Fisher CL, Vaillancourt R, Burnham KE.
Patient individuality: Uniphyl verus theo-dur 75
Fowler R.
New perspective on drug costs (Letter) 99
Strategies for maintaining professional competence. A manual for professional associations and faculties (Book Review) 141
Monitoring workload intensity (Letter) 260

Gardner DM, Hardy BG.
Cost-effectiveness of therapeutic drug monitoring 7
Georgieff T.
Shared use of opthalmic solutions 89
Gingrich RA, Wright D.
Propranolol and premature labour 137
Graham K.
see Semelman SA. 158

Halasi S, Nairn JG.
Stability of hydralazine hydrochloride in parenteral solutions 237
Hamilton D, Brown G, daSilva J.
Clinical pharmacy workload measurement: Pharmacokinetic and drug information services 203
Hardy BG.
see Gardner DM. 7
Hargreaves AP.
Congrats on new cover (Letter) 158
Hermolin RH, O'Grady SE.
Development and reversal of norfloxacin resistance in a strain of pseudomonas aeruginosa 30
Ho K, Bryson S, Leson C, Morris A.
High dose requirements for gentamicin in pediatric oncology patients 289

Iazzetta J.
see Walker S. 265
Ilersich AL.
see Ruth S. 109
Irwin D.
Neofax: a manual of drugs used in neonatal care. Second edition (Book Review) 92

Jackevicius C, Einarson T.
Utilization review of serum digoxin concentrations 273
Jimenez NV, Juan J, Ordovas JP, Ronchera CL.
Compatibility/stability of IV medications (Letter) 158
Juan J.
see Jimenez NV. 158

Julien JY.
The annual report (Letter) 5
Jung B, Andrews JD.
Effectiveness of an antibiotic cost containment measure 116

Kim-Sing A, Birmingham CL.
Clinical use of magnesium supplementation 161
King G.
CSHP — A "TEAM" approach (President's Report) 255
Improving our image (President's Report) 297
Koren G.
see Robieux IC. 235
Koren G, Tesoro A, Leeder JS, Bentur Y.
Stability of aqueous solutions of deferoxamine 57
Kozyrskyj A.
Surfactant therapy in the newborn 252
Kumar R.
see Robieux IC. 235

Landsberg KF, Davis SK.
Valproic acid in the treatment of mania 139
Lau DWC.
see Walker S. 265
Lavack L.
see Cameron A. 183
Lawrence R.
see Wolfe M. 243
Lazor-Bajcar JM.
Cefoxitin use review 221
Leeder JS.
see Koren G. 57
Leslie B.
Response to pharmacy misses out on recognition (Letter) 5
Leson C.
see Ho K. 289
Leson C. Bryson SM.
Oto-induced elevation of gentamicin concentrations 82

Macdonald DR.
see Reilly K. 27
Macdonald L.
Rational therapeutics: A clinical pharmacologic guide for the health professional 141
Mailhot C, Pharand C.
Thromboctopénie induite par l'indométhacine: rapport de cas et revue de la littérature 77
Massicotte A.
Quinidine preparations — a comparison 293
Meneilly G.
Maternal-fetal toxicology: A clinician's guide (Book Review) 253
Miyata M.
see Brown GR. 131
Morris A.
see Ho K. 289
Murdoch L.
Computer use in Canadian drug information centres 13
The exciting potential of electronic communication (Editorial) .. 45

Nairn JG.
Pharmaceutical dosage forms: Disperse systems. Volume 2 (Book Review) 37
see Halasi S. 237
Nakagawa RS.,
see Sonnichsen DS. 281
Nemethy EM, Collens SR.
Unit dose drug distribution in teaching hospitals: Key characteristics and centralized versus dencentralized approaches 61
Nessim D.
see Cameron A. 183

O'Brodovich M.
Redirecting pharmacist workload (Editorial) 95
O'Grady SE
see Hermolin RH. 30
Ordovas JP.
see Jimenez NV. 158
Otawa S.
Suppression of lactation 189

Paterson NAM.
see Devlin JW. 134
Payne L, Crone K. Pilla J.
Consultant pharmacists to assist with cost-containment and enhanced drug use management 247
Pharand C.
see Mailhot C. 77
Pilla J.
see Payne L. 247
Pipa D.
Medication manual for use in the neonatal intensive care unit: 3rd edition (Book Review) 253
Plosker G.
Is "full authority" too much authority? (Letter) 201
see Wolfe M. 243
Poulin S.
see Shevchuk YM. 49

Rhadakrishnan S.
see Robieux IC. 235
Reilly K, Collins D, Macdonald DR.
Permanent ataxia from phenytoin toxicity 27
Rescigno A.
New trends in pharmacokinetics (Letter) 48
Robert S.
Clonidine therapy in diabetic diarrhea 138
Robieux IC, Kumar R, Rhadakrishnan, Koren G.
The feasibility of using EMLA cream in pediatric outpatient clinics 235
Ronchera CL.
see Jimenez NV. 158
Rovers J.
see Cameron A. 183
Ruth S, Eagleson D, Ilersich AL.
Workload measurement in long term care pharmacy 109

Semelman SA, Graham K.
Missing out on recognition (Letter) 158
Saulnier LM.
see Tuttle CB. 90
Salsman B.
CSHP membership approves new bylaws (President's Report) .. 38
Task force to review the methods of conducting CSHP business (President's Report) 91
CSHP — Helping perfectionists in the imperfect world (President's Report) 143
CSHP — Promoting excellence in pharmacy services (President's Report) 193
Shevchuk YM, Poulin S.
Quality assurance and certification program for an aminoglycoside monitoring service 49
Silverman ED.
see Dupuis LL. 101
Sonnichsen DS, Nakagawa RS.
A drug utilization review of surgical prophylaxis in obstetrics and gynecology 281

Taddio A, Wilson W.
Bulk compounding in Canadian hospitals — a survey 213
Teri AM.
Doxapram for apnea of prematurity 32
Tesoro A.
see Koren G. 57
Thompson DF.
see Bennett J. 191
Tierney M.
Accreditation of hospital pharmacy residency programs: experience with on-site surveys 85
Treleaven S, Einarson TR.
Cost containment measures in hospital pharmacy: A bibliography 17
Tremblay S.
The elusive index medicus (Editorial) 155
Responding to reviewers' comments (Editorial) 197
Contributing to community patient care (Editorial) 259
Trottier L, Vanderveld C, Andrews D.
Possible adverse drug reaction involving topical metronidazole 249
Tuttle CB, Saulnier LM.
Alpha-adrenergic antagonists for bladder dysfunction 90

Vaillancourt R.
see Fisher CL. 75
Vanderveld C.
see Trottier L. 249

Walker S.
Something new (Editorial) 1
Encyclopedia of pharmaceutical technology Volume 1 (Book Review) 36
Chromatographic analysis of pharmaceuticals (Book Review) .. 192
Walker S, Lau DWC, DeAngelis C, Iazzetta J, Coons C.
Epirubicin stability in syringes and glass vials and evaluation of leaching plasticizers 265
Wilson W.
see Taddio A. 213
Wolfe M, Lawrence R, Plosker G.
Conversion from minibags to mini-infuser syringe pumps 243
Wong L.
Opthalmic mitomycin for preventing recurrent ptergium 251
Wright D.
see Gingrich RA. 137

Zahn D.
see Dupuis LL. 101

Subject Index

Accreditation
of hospital pharmacy residency programs 85
preparation for a CCHFA accreditation survey 183
Acetylsalicylic Acid
intolerancy 191
Adverse Drug Reactions
and misuse of TAC solution 190
and topical metronidazole 249
Alpha-Adrenergic Antagonists
for bladder dysfunction 90
Alprazolam Withdrawal
masquerading as steroid psychosis 134
Aminoglycosides
quality assurance and certification program 49
gentamicin use in pediatric oncology patients 289
Antibiotics
and cost containment 116
Apnea
doxapram for 32
Ataxia
from phenytoin toxicity 27

Beta Adrenergic Blockers
administration during pregnancy 137
Benzodiazepine Withdrawal
masquerading as steroid psychosis 134
Bioavailability
of an extemporaneous prednisone suspension 101
Bladder Dysfunction
and alpha-adrenergic antagonists 90

Book Reviews
Chromatogrpahic analysis of pharmaceuticals 192
Encyclopedia of pharmaceutical technology — Volume 1 36
Handbook of Applied Therapeutics — First edition 295
Medication manual for use in the neonatal intensive care unit — Third edition 253
Neofax: A manual of drugs used in neonatal care — Second edition 92
Pharmaceutical dosage forms: Disperse systems — Volume 2 37
Rational therapeutics: A clinical pharmacologic guide for the health professional 141
Strategies for maintaining professional competence. A manual for professional associations and faculties 141

Bylaws
CSHP membership approves (President's Report) 38
Bromocriptine
side effects of 189
Bulk Compounding
in Canadian hospitals 213

Canadian Journal of Hospital Pharmacy
CJHP Index to Advertisers 1:xvii, 2:xxi, 3:xix, 4:196, 5:xviii, 6:x
CJHP Objectives ..... i (all issues)
CJHP Table of Contents ..... iii (all issues)
CJHP Seeks Reviewers 200
Guidance for Authors 26, 56, 100, 172, 227, 6:xiii
Recommendations aux Auteurs 66, 108, 182, 228, 6:xiv
Tribute to Journal Volunteers 303
Tribute to Journal Reviewers 303
Tribute to Journal Translators 303
Policy for Publication of Chemical Stability Study Manuscripts 3
Politique pour la publication des manuscrits des études des stabilitiés chimiques 4
Canadian Society of Hospital Pharmacists
Abstract Reproduction Form 258
Annual General Meeting 299
Annual Report Notice 294
Appointment Form 199
Appointments 1:xvi, 47, 99, 159, 198, 263
Attention Theme 1990/91 241
Awards
24th Annual Awards Night Ceremonies 149
1989/90 Distinguished Service Award Recipient 151
1989/90 Meritorious Service Award Recipient 40
Call for 1990/91 Award Submissions 154
Deadline for 1990/91 Award Submissions 160
Nominations for Meritorious Service Award 60
Tribute to 1989/90 Awards Appraisers 150
Orest Buchko Retirement Notice 160
CFP Annual General Meeting Notice 160
CPA Conference Notice 3:xvii
CSHP Moving to Ottawa 2:x
CSHP Officers 1990/91 296
Call for Abstracts 73
Call for Posters and Contributed Oral Presentations 257
Call for Resolutions 60, 142
Corrections 37, 1:xii
Cytotoxic Symbol 2:xxiv
Grants to CSHP 154
Mission Statement 280
Notice of Bylaws Revision 142
Notice of Nominations for 1990/91 Officers 48, 142
Obituary 2:xviii
Oral Contributed Papers 41
Professional Practice Conference 145
Resolutions to 43rd Annual Meeting 302
Statement of Unit Dose and IV Admixture Drug Distribution 202
Cefazolin
and cost containment 116
in obstetrics and gynecology 281

Cefoxitin
use review 221
in obstetrics and gynecology 281
Certification
and quality assurance 49
Clindamycin
and cost containment 116
Clinical Functions
reorganization of 131
Clinical Pharmacy
physician assessment of 167
Clinical Services
and workload measurement 203
Clonidine
therapy in diabetic diarrhea 138
Cocaine
adverse reactions associated with 190
Community Patient Care
contributing to (Editorial) 259
Computers
and use in Canadian drug information centres 13
Consultant Pharmacists
and cost-containment 247
Containers
of parenteral solutions 237
Contamination
and shared use of opthalmic solutions 89

Corticosteroid-Induced Psychosis
and withdrawal 134
Cost Containment
in hospital pharmacy 17
and antibiotics 116
Cost-Effectiveness Analysis
and therapeutic drug monitoring 7

Deferoxamine
stability of aqueous solutions 57
Desensitization
of ASA-intolerant patients 191
Diabetics
and clonidine therapy for diarrhea 138
Diarrhea
diabetics and clonidine therapy 138
Digoxin
utilization review 273
Dosing Interval Interchange
of cefazolin, clindamycin and metronidazole 116
Doxapram
for apnea of prematurity 32
Drug Distribution Systems
in teaching hospitals 61
Drug Information
and computer use 13
and workload measurement 203
Drug Monitoring
and quality assurance 49
Drug Therapy
and pre-eclampsia 186
Drug Use Management
and consultant pharmacists 247
Drug Use Review
and cefoxitin 221
Drug Utilization Review
and cefoxitin 221
in obstetrics and gynecology 281

Editorials
Something new 1
The exciting potential of electronic communication 45
Redirecting pharmacist workload 95
The elusive index medicus 155
Responding to reviewers' comments 197
Contributing to community patient care 259
Electronic Communication
the exciting potential of (Editorial) 45
EMLA cream
use in pediatric outpatient clinics 235
Epinephrine
and racepinephrine administration 34
adverse reactions associated with 190
Epirubicin
stability 265

Gentamicin
oto-induced levels of concentrations 82
and pediatric oncology patients 289
Good Manufacturing Practices
and bulk compounding 213

Hydralazine Hydrochloride
in parenteral solutions 237
Hypermagnesemia
clinical manifestations of 161
Hypomagnesemia
clinical manifestations of 161

Index Medicus
the elusive (Editorial) 155
Interventions
physician assessment of 167
IV Additive Programs
and conversions 243

Lactation
suppression of 189
Letters to the Editor
The annual report 5
Pharmacy misses out on recognition 5
Response to "Pharmacy misses out on recognition" 5
Free trip 48
New trends in pharmacokinetics 48
New perspective on drug costs 99
Congrats on new cover 158
Misleading summary of cefoxitin 158
Missing out on recognition 158
Compatibility/stability of IV medications 158
Is "full authority" too much authority? 201
L'indométhacine
induit la thromboctopénie 77
Local anaesthetics
and the use of EMLA cream 235
Long Term Care
and workload measurement 109

Magnesium
supplementation 161
Mania
treatment with valproic acid 139

Metronidazole
and cost containment 116
topical adverse reaction from 249
Mini-infuser
syringe pumps 243
Mitomycin
for prevention of recurrent ptergium 251

Norfloxacin Resistance
development and reversal of 30

Oncology
gentamicin requirements in pediatrics 289
Opthalmic Solutions
shared use of 89
Outpatient Clinics
and the use of EMLA Cream 235

Packaging
and waste reduction 179
Pain
and the use of EMLA cream 235
Parenterals
and waste reduction packaging 179
Parenteral Solutions
and hydralazine hydrochloride 237
Pediatrics
and the use of EMLA cream 235
gentamicin use in oncology patients 289
Perfectionists
in the imperfect world 143
Pharmacist Workload
redirecting (Editorial) 95
Pharmacokinetic Monitoring
and cost-effectiveness 7
Pharmacokinetics
and quality assurance 49
and workload measurement 203
gentamicin and pediatric oncology patients 289
Pharmacy's Image
improving (President's Report) 297
Pharmacy Input
improving through reorganization 131
Pharmacy Services
unit dose drug distribution 61
promoting excellence in (President's Report) 193
Phenytoin Toxicity
permanent ataxia from 27
Phthalazine
in parenteral solutions 237
Plasticizers
leaching 265
Prazosin
and bladder dysfunction 90
Pre-eclampsia
in twin pregnancy 186
Prednisolone
and prednisone 101
Prednisone
extemporaneous suspension of 101
Premature Labour
and propranolol 137

President's Reports
CSHP membership approves new bylaws 38
Task force to review the methods of conducting CSHP business 93
CSHP — Helping perfectionists in the imperfect world 143
CSHP — Promoting excellence in pharmacy services 193
Improving our image 297
Productivity
and workload measurement 109
Propranolol
and premature labour 137
Pseudomonas Aeruginosa
and norfloxacin resistance 30

Quality Assurance
and estimating cost avoidance 167
Quality Assurance Program
for an aminoglycoside monitoring service 49
Quinidine
preparations 293

Racemic Mixtures
racepinephrine administration 34
Racepinephrine
administration to children 34
Recycling
and waste reduction 179
Residency Programs
accreditation of 85
Respiratory Distress Syndrome
and surfactant therapy 252
Reviewers' Comments
responding to (Editorial) 197

Serum Drug Level
utilization review 273
Something New
Editorial 1
Stability
of aqueous solutions of deferoxamine 57
of hydralazine hydrochloride 237
of epirubicin 265
Standards
for bulk compounding 213
Suppression
of lactation 189
Surfactant
therapy in the newborn 252
Surgical Prophylaxis
in obstetrics and gynecology 281
Suspensions
of prednisone and prednisolone 101
Syringes
and glass vials 265
Syringe Pumps
conversion to 243

TAC Solution
misuse of 190
Task Force
to review the methods of conduction CSHP business (President's Report) 93
Tetracaine
adverse reactions associated wtih 190
Theo-Dur
versus uniphyl 75
Therapeutic Drug Monitoring (TDM)
cost-effectiveness of 7

Thrombocytopénie
induite par l'indométhacine 77
Triazolam Withdrawal
masquerading as steroid psychosis 134
Uniphyl
versus theo-dur 75
Unit Dose
drug distribution 61
Utilization
review of serum digoxin concentrations 273
Valproic Acid
in the treatment of mania 139
Waste Reduction
and parenteral packaging 179
Workload Intensity
monitoring (Letter) 260
Workload Measurement
in long term care pharmacy 109
in clinical pharmacy 203

Advertisers' Index

Anaquest
Programs and Services 1:x; 3:ix
Astra Pharma Inc.
Polyamp ..... 2:xv, xxv; 3x, xx; 4:156, xvi; 5:xii, xix; 6:ii
Ayerst
Cefotan 2:67, 68, 69, 70, 71, 72; 3:125, 126, 127, 128, 129, 130; 4:173, 174, 175, 176, 177, 178; 5:229, 230, 231, 232, 233, 234
Canadian Armed Forces
Classified 1:2; 5:246; 6:262
Hoffmann-La Roche Limited
Rocephin ..... 4:x, xi; 5:xxvii, xxviii
Horner
Vincristine and Vinblastine 1:ii, 6, 16
H.G. Kalish Inc.
Hispac 2:x
Sargent XT 2:xxiv, 4:xxii
Kendall McGaw Canada
Excel 4:v
Knoll Pharmaceuticals
Dilaudid ..... 2:xxii, xxiii; 3:vi, vii; 4:ii, iv; 5:ii, iv; 6:x, xi, xii
Lyphomed Canada Inc.
Pediatric ..... 2:xxvi, IBC; 3:xxvi, IBC
Production Development 1:xi; 2:ii; 3:xi
Protamine Sulfate ..... 1:xx, IBC; 2:viii, ix
Research 4:IBC, 5:IBC
Vincristine ..... 6:xviii, IBC
Medicine Hat Regional Hospital
Classified 5:246
Merck Sharpe & Dohme Canada
Mefoxin ..... 1:xvi, xvii, xviii, xix; 3:xvi, xvii, xviii, xix 5:xvii, xviii, xx, xxi
Pepcid ..... 2:xix, xx, xxi; 3:ii, 123, 124; 4:xiii, xiv, xv 5:xiii, 219, 220
Miles Canada
Cipro ..... 2:xiv, xvi, xvii; 3:xiii, xiv, xv
Nordic Laboratories Inc.
Cardizem 3:xxi, 4:xii, 5:xxv
Novopharm Ltd.
Announcement 2:xxiv
Novo-Diltazen ..... 2:iv, v
Novo-Tamoxifen ..... 3:xxii, xxiii
Novo-Triolam ..... 1:iv, v
Unit Dose Packaging ..... 4:vi, vii; 5:xxii, xxiii; 6:iv, v
Pfizer Canada Inc.
Diffucon ..... 5:xiv, xv, xvi; 6:xv, xvi, xvii
Pharmascience
Lower Cost Alternatives 6:IFC
Statex 1:IFC; 2:IFC; 3:IFC; 4:IFC; 5:IFC
Purdue Frederick Inc.
MS Contin 1:OBC; 2:OBC; 3:OBC; 4:OBC; 5:OBC; 6:OBC
Rhône-Poulenc Pharma Inc.
Tamofen 3:xv
Roussel Canada Inc.
Claforan 3:97, 98
Add-Vantage 5:211, 212
Sabex
Dexamethasone ..... 6:264, vii
Morphine HP ..... 1:vi, vii; 2:vi, vii; 3:xxiv, xxv; 4:viii, ix; 5:v
Sandoz
Corporate 6:262
Smith, Kline & French Canada Ltd.
Cefizox ..... 1:xiii, xiv, xv; 2:xi, xii, xiii; 3:xii, 106, 107; 4:xix, xx, xxi; 5:ix, x, xi
Smith & Nephew
Small Volume Generic Parenterals 2:xvii; 3:viii; 4:xxii
Squibb Canada Inc.
Corporate 5:viii
Capoten ..... 5:xxix, xxx, xxxi; 6:vi, viii, ix
Supply & Services Canada
Classified ..... 5:xxiv, xxvi
The Upjohn Company of Canada
Dalcin C ..... 1:viii, ix; 3:iv, v; 4:xvii, xviii; 5:vi, vii